Written by The Business Journal Staff
The Federal Trade Commission is taking action against a Berkeley-based medical supply company for selling a supplement it said could prevent Covid-19.
The complaint filed by the FTC is seeking to induce Precision Patient Outcomes, Inc. and the company’s CEO Margrett Lewis to stop making unsubstantiated claims its supplements can treat and prevent Covid-19, according to a news release.
Precision Patient Outcomes created, labeled, advertised, distributed and sold the supplements under the names COVID Resist and Virus Resist.
The two supplements are not much more than a cocktail of vitamins and minerals, according to a press release from the FTC.
But in May 2021, the company marketed on its website and social media claims about the supplement’s effectiveness against the virus. After knowing about the FTC’s enforcement actions against other companies, the company rebranded COVID Resist to Virus Resist, the release stated. The FTC contends the company continued to advertise it as an effective treatment against Covid.
Civil penalties are being sought against the company under the COVID-19 Consumer Protection Act.